Authorization lapses
Infusions denied after authorization expiry. We track expiry dates and renew ahead of the next dose.
Home / Specialties / Rheumatology
Rheumatology revenue depends on infusion and injection services as much as on visits: biologics, infusion administration, joint injections and the prior authorizations and specialty-pharmacy decisions behind them. Our billing protects the drug margin and keeps authorizations ahead of treatment.
General billers treat every specialty the same. These are the rules, code families and payer habits that decide whether rheumatology claims pay the first time.
Every denial gets a root cause, a fix and a feedback loop, so the same denial stops coming back.
Infusions denied after authorization expiry. We track expiry dates and renew ahead of the next dose.
Underpaid or denied drug lines. Units converted and wastage modifiers applied.
Joint injections denied for guidance or joint size errors. Coded from the note.
A dedicated team that already knows your payers' rules, plus the reporting to prove it is working. Credentialing for new rheumatology providers runs in the same system, tracked live in your client portal.
The full revenue cycle as standard for rheumatology practices, priced on what we collect for you. Take all of it, or start with one piece such as AR recovery or credentialing.
By keeping authorizations ahead of treatment, converting doses to billing units correctly and reporting wastage the way each payer requires.
It depends on the drug and payer. We report margin by agent so you can decide on numbers rather than habit.
Yes, with the correct code for joint size and guidance and the drug billed separately.
Send us your specialty, provider count and monthly claim volume through the quote form and we will come back with a written proposal. Transitions run alongside your current billing so nothing is dropped, and credentialing for new rheumatology providers can start at the same time.
Send us a snapshot of your current billing and we will come back with a quote and a realistic view of recoverable revenue.